Search results

1. Jazz joins the KRAS band with Redx deal

   … which produced promising data – with caveats – at ESMO 2023. Quanta is taking an interesting approach, with … KRAS G12D siRNA Ph2 in pancreatic cancer; ESMO 2023: no difference in OS vs chemo MRTX1133 … KRAS G12D inhibitor Lacklustre ph1 data at ESMO 2023 (1/18 PRs) ASP3082 Astellas KRAS G12D …

   
    

   Madeleine Armstrong
    
   - 02/08/2024 - 13:03

2. A cancer pipeline cull from AbbVie

   … payload) Ph1 in solid tumours Data at ESMO 2023 in NSCLC: ORR 14% in 3L & 10% in 2L … SHP2 inhibitor Ph1/2 in solid tumours Data at ESMO 2023 + glecirasib (KRAS G12C) in NSCLC: ORR 51% …

   
    

   Madeleine Armstrong
    
   - 02/06/2024 - 13:49

3. Pfizer shuffles its deck post-Seagen

   … Beijing Immunochina Early China ph1 ; data at ESMO 2023: ORR 11% in 9 pts GCC19CART Car-T …

   
    

   Madeleine Armstrong
    
   - 02/01/2024 - 14:51

4. Roche walks away from Hookipa’s KRAS immunotherapy

   … immunotherapy HPV16+ HNSCC Ph1/2 1L + Keytruda ESMO 2023: 42% ORR (8/19 pts); more data due H1 2024; …

   
    

   Madeleine Armstrong
    
   - 01/30/2024 - 13:42

5. Trodelvy throws second-line lung cancer another curveball

   … and a secondary endpoint in Evoke-01. Source: ESMO 2023 & Gilead press release. Trial …

   
    

   Jacob Plieth
    
   - 01/23/2024 - 15:04

6. ASCO-GI – Jacobio’s KRAS looks competitive in pancreatic

   … cancer with its multi-RAS inhibitor RMC-6236 at ESMO 2023; however, this study excluded G12C mutants. …

   
    

   Madeleine Armstrong
    
   - 01/18/2024 - 14:56

7. ASCO-GU preview: showdown for Exelixis

   … in neuroendocrine prostate cancer 121 Had data at ESMO 2023; company sold to Merck & Co Keynote-564 …

   
    

   Jacob Plieth
    
   - 01/25/2024 - 10:22

8. Cell cycle niche seeks clinical validation

   … +/- platinum chemo, started Aug 2023; preclinical data at ESMO 2023 AZD8421 AstraZeneca Cycad-1 trial …

   
    

   Jacob Plieth
    
   - 01/12/2024 - 17:23

9. J&J deal cements Ambrx’s transformation

   … cohorts 4-8 the confirmed ORR was 22%.   Source: ESMO 2023.   Any lingering doubts now become …

   
    

   Jacob Plieth
    
   - 01/10/2024 - 14:31

10. Merck’s latest move is in bispecifics

    … toxicity.  In a phase 1/2 study presented at ESMO 2023 HPN328 produced a confirmed response rate of 32% … house Ph1 +/- Keytruda in solid tumours ; data at ESMO 2023 Not yet given Source: Mizuho note, …

    
     

    Madeleine Armstrong
     
    - 06/19/2024 - 16:48